Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer

Conclusion PDAC tumours of women are more sensitive to gemcitabine-based nCRT, resulting in longer OS after resection compared with men. This may be due to enhanced immunity impeding the infiltration of protumoral M2 macrophages into the TME. Our findings highlight the importance of considering sex disparities and mitigating immunosuppressive macrophage polarisation for personalised PDAC treatment.

http://gut.bmj.com/cgi/content/short/73/2/311?rss=1

Source: Gut - January 5, 2024 Category: Gastroenterology Authors: van Eijck, C. W. F., Mustafa, D. A. M., Vadgama, D., de Miranda, N. F. C. C., Groot Koerkamp, B., van Tienhoven, G., van der Burg, S. H., Malats, N., van Eijck, C. H. J., Dutch Pancreatic Cancer Group (DPCG) Tags: Open access, Gut Pancreas Source Type: research